Skip to main content

Wise John Drayton's Form 4 filing

INSMED Inc (INSM) · filed Jan 5, 2024

Accession no.
0001628280-24-000698
Filed
Jan 5, 2024
Trade date
Jan 3-5, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $620.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wise John DraytonCIK 0001930805Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2024Stock Option (right to buy)MOption exerciseAcquired+20,071$19.11+$383,556.81124,055Direct
Jan 3, 2024Stock Option (right to buy)SSaleDisposed−20,071$29.19F3−$585,872.49103,984Direct
Jan 4, 2024Common StockAGrant or awardAcquired+12,873–F5–116,857Direct
Jan 5, 2024Common StockSSaleDisposed−1,167$29.32−$34,216.44115,690Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2024Common StockMOption exerciseDisposed−20,071$0.00$00Direct
Jan 4, 2024Common StockAGrant or awardAcquired+63,560$0.00$063,560Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

This is the weighted average sales price representing 20,071 shares sold at prices ranging from $28.915 to $29.39 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Referenced by the price of 1 transaction in Table I.

F5

Each Restricted Stock Unit was received as a grant on January 4, 2024, for no consideration.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)